The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators-A pilot study

Marek Kucera, David Balaz, Peter Kruzliak, Rachele Ciccocioppo, Stanislav Oravec, Luis Rodrigo, Anthony Zulli, Eva Hirnerova, Peter Sabaka, Andrea Komornikova, Jan Sabo, Peter Slezak, Ludovit Gaspar

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objectives: The mean platelet volume (MPV) and red cell distribution width (RDW) have recently arisen interest because of their association with an increased cardiovascular risk. The aim of our study was, therefore, to determine whether an association exists between MPV, RDW and lipoprotein sub-fractions, and to show the impact of statin therapy on these new possible biomarkers of atherosclerotic risk. Design and methods: A cohort of 40 patients with hypercholesterolaemia (29 females, mean age 62.9. ±. 9. years), without previous hypolipidaemic treatment were enrolled. The patients were treated with atorvastatin 40. mg/day for 12. weeks. Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density cholesterol (HDL-C), triglycerides (TG), LDL-C sub-fractions [large LDL-C 1-2 and small dense (sd)-LDL-C 3-7], apolipoproteins (apoA1, apoB), apoB/apoA1 ratio, atherogenic index of plasma (AIP), haematological parameters (including MPV, RDW) and safety parameters (renal, hepatic) were measured before and after 12. weeks of atorvastatin treatment. Results: At baseline, a strong correlation between HDL-C, TG, sd-LDL-C, apoB, apoB/apoA1, and AIP with MPV (. r=. -. 0.55, p

Original languageEnglish
Pages (from-to)557-561
Number of pages5
JournalClinical Biochemistry
Volume48
Issue number9
DOIs
Publication statusPublished - Jun 1 2015

Fingerprint

Mean Platelet Volume
Erythrocyte Indices
Dyslipidemias
Platelets
LDL Cholesterol
Apolipoproteins B
Cells
Plasmas
Triglycerides
Association reactions
Therapeutics
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Apolipoproteins
Cholesterol
Biomarkers
Hypercholesterolemia
LDL Lipoproteins
HDL Cholesterol
Lipoproteins
Atorvastatin Calcium

Keywords

  • Atherogenic dyslipidaemia
  • Atorvastatin
  • Dense LDL
  • Mean platelet volume
  • Red cell distribution width
  • Small

ASJC Scopus subject areas

  • Clinical Biochemistry

Cite this

The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators-A pilot study. / Kucera, Marek; Balaz, David; Kruzliak, Peter; Ciccocioppo, Rachele; Oravec, Stanislav; Rodrigo, Luis; Zulli, Anthony; Hirnerova, Eva; Sabaka, Peter; Komornikova, Andrea; Sabo, Jan; Slezak, Peter; Gaspar, Ludovit.

In: Clinical Biochemistry, Vol. 48, No. 9, 01.06.2015, p. 557-561.

Research output: Contribution to journalArticle

Kucera, Marek ; Balaz, David ; Kruzliak, Peter ; Ciccocioppo, Rachele ; Oravec, Stanislav ; Rodrigo, Luis ; Zulli, Anthony ; Hirnerova, Eva ; Sabaka, Peter ; Komornikova, Andrea ; Sabo, Jan ; Slezak, Peter ; Gaspar, Ludovit. / The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators-A pilot study. In: Clinical Biochemistry. 2015 ; Vol. 48, No. 9. pp. 557-561.
@article{fbe4f8beb2a647fcaa54bc0329fe0284,
title = "The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators-A pilot study",
abstract = "Objectives: The mean platelet volume (MPV) and red cell distribution width (RDW) have recently arisen interest because of their association with an increased cardiovascular risk. The aim of our study was, therefore, to determine whether an association exists between MPV, RDW and lipoprotein sub-fractions, and to show the impact of statin therapy on these new possible biomarkers of atherosclerotic risk. Design and methods: A cohort of 40 patients with hypercholesterolaemia (29 females, mean age 62.9. ±. 9. years), without previous hypolipidaemic treatment were enrolled. The patients were treated with atorvastatin 40. mg/day for 12. weeks. Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density cholesterol (HDL-C), triglycerides (TG), LDL-C sub-fractions [large LDL-C 1-2 and small dense (sd)-LDL-C 3-7], apolipoproteins (apoA1, apoB), apoB/apoA1 ratio, atherogenic index of plasma (AIP), haematological parameters (including MPV, RDW) and safety parameters (renal, hepatic) were measured before and after 12. weeks of atorvastatin treatment. Results: At baseline, a strong correlation between HDL-C, TG, sd-LDL-C, apoB, apoB/apoA1, and AIP with MPV (. r=. -. 0.55, p",
keywords = "Atherogenic dyslipidaemia, Atorvastatin, Dense LDL, Mean platelet volume, Red cell distribution width, Small",
author = "Marek Kucera and David Balaz and Peter Kruzliak and Rachele Ciccocioppo and Stanislav Oravec and Luis Rodrigo and Anthony Zulli and Eva Hirnerova and Peter Sabaka and Andrea Komornikova and Jan Sabo and Peter Slezak and Ludovit Gaspar",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.clinbiochem.2015.02.010",
language = "English",
volume = "48",
pages = "557--561",
journal = "Clinical Biochemistry",
issn = "0009-9120",
publisher = "Elsevier Inc.",
number = "9",

}

TY - JOUR

T1 - The effects of atorvastatin treatment on the mean platelet volume and red cell distribution width in patients with dyslipoproteinemia and comparison with plasma atherogenicity indicators-A pilot study

AU - Kucera, Marek

AU - Balaz, David

AU - Kruzliak, Peter

AU - Ciccocioppo, Rachele

AU - Oravec, Stanislav

AU - Rodrigo, Luis

AU - Zulli, Anthony

AU - Hirnerova, Eva

AU - Sabaka, Peter

AU - Komornikova, Andrea

AU - Sabo, Jan

AU - Slezak, Peter

AU - Gaspar, Ludovit

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Objectives: The mean platelet volume (MPV) and red cell distribution width (RDW) have recently arisen interest because of their association with an increased cardiovascular risk. The aim of our study was, therefore, to determine whether an association exists between MPV, RDW and lipoprotein sub-fractions, and to show the impact of statin therapy on these new possible biomarkers of atherosclerotic risk. Design and methods: A cohort of 40 patients with hypercholesterolaemia (29 females, mean age 62.9. ±. 9. years), without previous hypolipidaemic treatment were enrolled. The patients were treated with atorvastatin 40. mg/day for 12. weeks. Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density cholesterol (HDL-C), triglycerides (TG), LDL-C sub-fractions [large LDL-C 1-2 and small dense (sd)-LDL-C 3-7], apolipoproteins (apoA1, apoB), apoB/apoA1 ratio, atherogenic index of plasma (AIP), haematological parameters (including MPV, RDW) and safety parameters (renal, hepatic) were measured before and after 12. weeks of atorvastatin treatment. Results: At baseline, a strong correlation between HDL-C, TG, sd-LDL-C, apoB, apoB/apoA1, and AIP with MPV (. r=. -. 0.55, p

AB - Objectives: The mean platelet volume (MPV) and red cell distribution width (RDW) have recently arisen interest because of their association with an increased cardiovascular risk. The aim of our study was, therefore, to determine whether an association exists between MPV, RDW and lipoprotein sub-fractions, and to show the impact of statin therapy on these new possible biomarkers of atherosclerotic risk. Design and methods: A cohort of 40 patients with hypercholesterolaemia (29 females, mean age 62.9. ±. 9. years), without previous hypolipidaemic treatment were enrolled. The patients were treated with atorvastatin 40. mg/day for 12. weeks. Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density cholesterol (HDL-C), triglycerides (TG), LDL-C sub-fractions [large LDL-C 1-2 and small dense (sd)-LDL-C 3-7], apolipoproteins (apoA1, apoB), apoB/apoA1 ratio, atherogenic index of plasma (AIP), haematological parameters (including MPV, RDW) and safety parameters (renal, hepatic) were measured before and after 12. weeks of atorvastatin treatment. Results: At baseline, a strong correlation between HDL-C, TG, sd-LDL-C, apoB, apoB/apoA1, and AIP with MPV (. r=. -. 0.55, p

KW - Atherogenic dyslipidaemia

KW - Atorvastatin

KW - Dense LDL

KW - Mean platelet volume

KW - Red cell distribution width

KW - Small

UR - http://www.scopus.com/inward/record.url?scp=84929945116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929945116&partnerID=8YFLogxK

U2 - 10.1016/j.clinbiochem.2015.02.010

DO - 10.1016/j.clinbiochem.2015.02.010

M3 - Article

VL - 48

SP - 557

EP - 561

JO - Clinical Biochemistry

JF - Clinical Biochemistry

SN - 0009-9120

IS - 9

ER -